Home NDC 0469-1425-70 Xospata
Product NDC 0469-1425
Requested package NDC 0469-1425-70
11-digit product format 004691425
Labeler code 0469
Product ID 0469-1425_cee167a0-32ac-4cc2-957b-a10b685ed206
Type HUMAN PRESCRIPTION DRUG
Nonproprietary name gilteritinib
Dosage form TABLET
Route ORAL
Labeler Astellas Pharma US, Inc.
Application NDA211349
Marketing category NDA
Marketing start 2018-11-29
Substance GILTERITINIB FUMARATE
Active strength 40 mg/1
NDC exclude flag No
Listing certified through 2027-12-31
Current FDA listing Yes Source provenance: Browse the complete Orange Book source catalog · source snapshot 45 .
Orange Book products# Current product rows page 1 of 1 · 1 matching rows.
Application-product, Trade name, Ingredient table Application-product Trade name Ingredient Strength Dosage form / route TE codes RLD / RS Approval date N211349-001 XOSPATA GILTERITINIB FUMARATE EQ 40MG BASE TABLET / ORAL RLD, RS 2018-11-28
Orange Book patents# Current patent rows page 1 of 1 · 8 matching rows.
Application-product, Patent, Expiration table Application-product Patent Expiration Use code Coverage / status Submission date N211349-001 9487491 2030-07-28 U-2456 2018-12-18 N211349-001 8969336 2032-11-28 Drug substance, Drug product 2018-12-18 N211349-001 10786500 2036-07-01 Drug product 2020-10-28 N211349-001 11938130 2036-07-01 Drug product 2024-04-25 N211349-001 11938131 2036-07-01 Drug product 2024-04-25 N211349-001 11938132 2036-07-01 Drug product 2024-04-25 N211349-001 11938133 2036-07-01 Drug product 2024-04-25 N211349-001 11944620 2036-07-01 Drug product 2024-04-25
Observed Orange Book product history# Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
Product history page 1 of 2 · 45 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Trade name Strength Dosage form / route Product TE source text RLD / RS Approval date Source SHA-256 2026-11-14 07:37:17 2026-10 N211349-001 XOSPATA EQ 40MG BASE TABLET / ORAL RLD, RS 2018-11-28 d4dbc9d85df4…2026-10-15 13:18:30 2026-09 N211349-001 XOSPATA EQ 40MG BASE TABLET / ORAL RLD, RS 2018-11-28 c2088c7a36db…2026-09-14 22:38:34 2026-08 N211349-001 XOSPATA EQ 40MG BASE TABLET / ORAL RLD, RS 2018-11-28 84e616aacf4f…2026-08-18 06:07:40 2026-07 N211349-001 XOSPATA EQ 40MG BASE TABLET / ORAL RLD, RS 2018-11-28 caaa826d4ba7…2026-02-19 14:30 UTC 2026-02 N211349-001 XOSPATA EQ 40MG BASE TABLET / ORAL RLD, RS 2018-11-28 011fe1cb6892…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N211349-001 XOSPATA EQ 40MG BASE TABLET / ORAL RLD, RS 2018-11-28 31067a03dcf5…2025-08-23 18:47 UTC 2025-08 N211349-001 XOSPATA EQ 40MG BASE TABLET / ORAL RLD, RS 2018-11-28 6a471c1ec25d…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N211349-001 XOSPATA EQ 40MG BASE TABLET / ORAL RLD, RS 2018-11-28 fd3edfee7708…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 N211349-001 XOSPATA EQ 40MG BASE TABLET / ORAL RLD, RS 2018-11-28 b8a1b40f171c…2025-01-19 17:59 UTC · 7 captures of this ZIP 2025-01 N211349-001 XOSPATA EQ 40MG BASE TABLET / ORAL RLD, RS 2018-11-28 03ed91905a0d…2024-12-13 21:23 UTC · 2 captures of this ZIP 2024-12 N211349-001 XOSPATA EQ 40MG BASE TABLET / ORAL RLD, RS 2018-11-28 2680178bc6a6…2024-09-14 05:58 UTC · 2 captures of this ZIP 2024-09 N211349-001 XOSPATA EQ 40MG BASE TABLET / ORAL RLD, RS 2018-11-28 5bbf6a4d5a75…2024-11-08 22:44 UTC · 3 captures of this ZIP 2024-11 N211349-001 XOSPATA EQ 40MG BASE TABLET / ORAL RLD, RS 2018-11-28 d8e5a09893c0…2024-10-29 15:01 UTC 2024-10 N211349-001 XOSPATA EQ 40MG BASE TABLET / ORAL RLD, RS 2018-11-28 d06236e962d9…2024-08-13 05:28 UTC · 3 captures of this ZIP 2024-08 N211349-001 XOSPATA EQ 40MG BASE TABLET / ORAL RLD, RS 2018-11-28 79d66fd596c7…2024-07-13 05:37 UTC · 2 captures of this ZIP 2024-07 N211349-001 XOSPATA EQ 40MG BASE TABLET / ORAL RLD, RS 2018-11-28 301d65b070ca…2024-06-18 03:08 UTC · 5 captures of this ZIP 2024-06 N211349-001 XOSPATA EQ 40MG BASE TABLET / ORAL RLD, RS 2018-11-28 1e350fbaab3a…2024-05-31 18:47 UTC 2024-05 N211349-001 XOSPATA EQ 40MG BASE TABLET / ORAL RLD, RS 2018-11-28 8072bd15b7f6…2022-06-29 02:47 UTC · 2 captures of this ZIP 2022-06 N211349-001 XOSPATA EQ 40MG BASE TABLET / ORAL RLD, RS 2018-11-28 5c6f7cd8ea54…2022-04-08 23:34 UTC 2022-04 N211349-001 XOSPATA EQ 40MG BASE TABLET / ORAL RLD, RS 2018-11-28 5d02ea3f76ae…2022-04-04 05:41 UTC 2022-04 N211349-001 XOSPATA EQ 40MG BASE TABLET / ORAL RLD, RS 2018-11-28 4b0b4de00fa7…2019-12-13 00:20 UTC 2019-12 N211349-001 XOSPATA EQ 40MG BASE TABLET / ORAL RLD, RS 2018-11-28 74a2ff9319b5…2022-03-09 01:35 UTC 2022-03 N211349-001 XOSPATA EQ 40MG BASE TABLET / ORAL RLD, RS 2018-11-28 bb7c543d1eb4…2021-12-28 21:50 UTC 2021-12 N211349-001 XOSPATA EQ 40MG BASE TABLET / ORAL RLD, RS 2018-11-28 782e0a99824c…2021-05-05 16:15 UTC · 3 captures of this ZIP 2021-05 N211349-001 XOSPATA EQ 40MG BASE TABLET / ORAL RLD, RS 2018-11-28 87673890dc5c…2021-03-12 10:30 UTC 2021-03 N211349-001 XOSPATA EQ 40MG BASE TABLET / ORAL RLD, RS 2018-11-28 5aa47cf7b7d7…2020-12-22 03:56 UTC 2020-12 N211349-001 XOSPATA EQ 40MG BASE TABLET / ORAL RLD, RS 2018-11-28 8869cabd3fbd…2020-11-12 02:37 UTC 2020-11 N211349-001 XOSPATA EQ 40MG BASE TABLET / ORAL RLD, RS 2018-11-28 c0c555d07b60…2019-12-14 00:12 UTC 2019-12 N211349-001 XOSPATA EQ 40MG BASE TABLET / ORAL RLD, RS 2018-11-28 3f01610625f2…2019-09-15 20:21 UTC 2019-09 N211349-001 XOSPATA EQ 40MG BASE TABLET / ORAL RLD, RS 2018-11-28 b00525d2431f…2019-07-19 19:46 UTC 2019-07 N211349-001 XOSPATA EQ 40MG BASE TABLET / ORAL RLD, RS 2018-11-28 ea99ee380514…2024-03-16 18:09 UTC · 4 captures of this ZIP 2024-03 N211349-001 XOSPATA EQ 40MG BASE TABLET / ORAL RLD, RS 2018-11-28 6a51e52b5d6a…2024-02-18 07:12 UTC 2024-02 N211349-001 XOSPATA EQ 40MG BASE TABLET / ORAL RLD, RS 2018-11-28 1c564ffb4f44…2023-12-20 04:57 UTC 2023-12 N211349-001 XOSPATA EQ 40MG BASE TABLET / ORAL RLD, RS 2018-11-28 ea1830bbd6c7…2023-11-28 05:40 UTC · 2 captures of this ZIP 2023-11 N211349-001 XOSPATA EQ 40MG BASE TABLET / ORAL RLD, RS 2018-11-28 a72a2bbeb626…2023-10-25 00:34 UTC · 2 captures of this ZIP 2023-10 N211349-001 XOSPATA EQ 40MG BASE TABLET / ORAL RLD, RS 2018-11-28 9b2671bbb829…2023-07-15 15:27 UTC · 2 captures of this ZIP 2023-07 N211349-001 XOSPATA EQ 40MG BASE TABLET / ORAL RLD, RS 2018-11-28 a67488948f0b…2023-06-13 01:57 UTC · 3 captures of this ZIP 2023-06 N211349-001 XOSPATA EQ 40MG BASE TABLET / ORAL RLD, RS 2018-11-28 3f0d92c62455…2023-05-13 08:27 UTC 2023-05 N211349-001 XOSPATA EQ 40MG BASE TABLET / ORAL RLD, RS 2018-11-28 053a50430f4f…2023-01-26 05:58 UTC 2023-01 N211349-001 XOSPATA EQ 40MG BASE TABLET / ORAL RLD, RS 2018-11-28 3bdfa0b2c4d7…
Observed Orange Book patent history# Patent history page 1 of 6 · 226 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Patent Expiration Use code Coverage / status Submission date Source SHA-256 2026-11-14 07:37:17 2026-10 N211349-001 9487491 2030-07-28 U-2456 2018-12-18 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N211349-001 8969336 2032-11-28 Drug substance, Drug product 2018-12-18 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N211349-001 10786500 2036-07-01 Drug product 2020-10-28 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N211349-001 11938130 2036-07-01 Drug product 2024-04-25 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N211349-001 11938131 2036-07-01 Drug product 2024-04-25 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N211349-001 11938132 2036-07-01 Drug product 2024-04-25 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N211349-001 11938133 2036-07-01 Drug product 2024-04-25 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N211349-001 11944620 2036-07-01 Drug product 2024-04-25 d4dbc9d85df4…2026-10-15 13:18:30 2026-09 N211349-001 9487491 2030-07-28 U-2456 2018-12-18 c2088c7a36db…2026-10-15 13:18:30 2026-09 N211349-001 8969336 2032-11-28 Drug substance, Drug product 2018-12-18 c2088c7a36db…2026-10-15 13:18:30 2026-09 N211349-001 10786500 2036-07-01 Drug product 2020-10-28 c2088c7a36db…2026-10-15 13:18:30 2026-09 N211349-001 11938130 2036-07-01 Drug product 2024-04-25 c2088c7a36db…2026-10-15 13:18:30 2026-09 N211349-001 11938131 2036-07-01 Drug product 2024-04-25 c2088c7a36db…2026-10-15 13:18:30 2026-09 N211349-001 11938132 2036-07-01 Drug product 2024-04-25 c2088c7a36db…2026-10-15 13:18:30 2026-09 N211349-001 11938133 2036-07-01 Drug product 2024-04-25 c2088c7a36db…2026-10-15 13:18:30 2026-09 N211349-001 11944620 2036-07-01 Drug product 2024-04-25 c2088c7a36db…2026-09-14 22:38:34 2026-08 N211349-001 9487491 2030-07-28 U-2456 2018-12-18 84e616aacf4f…2026-09-14 22:38:34 2026-08 N211349-001 8969336 2032-11-28 Drug substance, Drug product 2018-12-18 84e616aacf4f…2026-09-14 22:38:34 2026-08 N211349-001 10786500 2036-07-01 Drug product 2020-10-28 84e616aacf4f…2026-09-14 22:38:34 2026-08 N211349-001 11938130 2036-07-01 Drug product 2024-04-25 84e616aacf4f…2026-09-14 22:38:34 2026-08 N211349-001 11938131 2036-07-01 Drug product 2024-04-25 84e616aacf4f…2026-09-14 22:38:34 2026-08 N211349-001 11938132 2036-07-01 Drug product 2024-04-25 84e616aacf4f…2026-09-14 22:38:34 2026-08 N211349-001 11938133 2036-07-01 Drug product 2024-04-25 84e616aacf4f…2026-09-14 22:38:34 2026-08 N211349-001 11944620 2036-07-01 Drug product 2024-04-25 84e616aacf4f…2026-08-18 06:07:40 2026-07 N211349-001 9487491 2030-07-28 U-2456 2018-12-18 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N211349-001 8969336 2032-11-28 Drug substance, Drug product 2018-12-18 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N211349-001 10786500 2036-07-01 Drug product 2020-10-28 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N211349-001 11938130 2036-07-01 Drug product 2024-04-25 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N211349-001 11938131 2036-07-01 Drug product 2024-04-25 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N211349-001 11938132 2036-07-01 Drug product 2024-04-25 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N211349-001 11938133 2036-07-01 Drug product 2024-04-25 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N211349-001 11944620 2036-07-01 Drug product 2024-04-25 caaa826d4ba7…2026-02-19 14:30 UTC 2026-02 N211349-001 9487491 2030-07-28 U-2456 2018-12-18 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N211349-001 8969336 2032-11-28 Drug substance, Drug product 2018-12-18 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N211349-001 10786500 2036-07-01 Drug product 2020-10-28 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N211349-001 11938130 2036-07-01 Drug product 2024-04-25 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N211349-001 11938131 2036-07-01 Drug product 2024-04-25 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N211349-001 11938132 2036-07-01 Drug product 2024-04-25 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N211349-001 11938133 2036-07-01 Drug product 2024-04-25 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N211349-001 11944620 2036-07-01 Drug product 2024-04-25 011fe1cb6892…
Observed Orange Book exclusivity history# Exclusivity history page 1 of 2 · 63 observed states.
Reported adverse events (FAERS/openFDA)# Adverse event summaries are temporarily unavailable. Other product information remains available.
Additional Listing Data#
Finished product Yes
Brand name base Xospata
Listing expiration 2027-12-31 Active Ingredients# Ingredient, Strength table Ingredient Strength GILTERITINIB FUMARATE 40 mg/1
Harmonized UNII identifiers# UNII identifiers page 1 of 1 · 1 matching rows.
Identifier, FDA.report destination table Identifier FDA.report destination 5RZZ0Z1GJT Internal UNII lookup
Harmonized RxCUI identifiers# RxCUI identifiers page 1 of 1 · 2 matching rows.
Identifier, FDA.report destination table Identifier FDA.report destination 2105811 Internal RxNorm lookup 2105817 Internal RxNorm lookup
Harmonized SPL set identifiers# SPL set identifiers page 1 of 1 · 1 matching rows.
DailyMed Product Concepts# DailyMed Package Descriptions# DailyMed Dashboard NDC Coverage# NDC, Dashboard title, SPL version table NDC Dashboard title SPL version Validation Dashboard ZIP 0469-1425 XOSPATA (GILTERITINIB) TABLET [ASTELLAS PHARMA US, INC.] 10 Current NDC, Legacy NDC, 4 package rows 20250125_b5ff59aa-9c0d-49a8-9053-1f179b482383.zip
openFDA label cross-check# OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
Matched openFDA labels page 1 of 1 · 1 matching rows.
DailyMed RxNorm Mappings# Packages# Package NDC, 11-digit format, Description table Package NDC 11-digit format Description Units Marketing start Sample Exclude flag Status 0469-1425-70 00469142570 1 BOTTLE in 1 CARTON (0469-1425-70) / 21 TABLET in 1 BOTTLE 1 bottle 2026-11-02 No No Current